Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Developing Antitussive Alternatives To DXM Would Offset Commercial Risk

This article was originally published in The Tan Sheet

Executive Summary

Expert advisors to FDA encourage firms to develop new OTC cough suppressants to replace dextromethorphan, which some argue is ineffective and poses an abuse risk

You may also be interested in...



US Would Cough Up As Much As $31bn More For Rx-Only DXM Over 10 Years

A study the Consumer Healthcare Products Association commissioned finds OTC access to the cough suppressant dextromethorphan will save consumers between $22bn and $31bn through 2025 compared to a scenario of the product moving to Rx-only.

US Would Cough Up As Much As $31bn More For Rx-Only DXM Over 10 Years

A study the Consumer Healthcare Products Association commissioned finds OTC access to the cough suppressant dextromethorphan will save consumers between $22bn and $31bn through 2025 compared to a scenario of the product moving to Rx-only.

Study Shows Antitussive Efficacy For Diphenhydramine, Less For DXM

Diphenhydramine, a common antihistamine in cough/cold OTCs, proves more effective in suppressing cough than the common antitussive dextromethorphan, researchers say. Diphenhydramine is in FDA’s antitussive OTC monograph, but marketers are criticized for not demonstrating its and other cough/cold ingredients’ efficacy in trials.

Related Content

Topics

UsernamePublicRestriction

Register

PS104533

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel